Navigation Links
Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
Date:7/2/2012

EAST BRUNSWICK, N.J., July 2, 2012 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced a new publication showing that adult patients with refractory chronic gout (RCG) treated bi-weekly with KRYSTEXXA (pegloticase) experienced statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL), pain and physical function. The article confirms that chronic gout, especially refractory chronic gout, is associated with decline in HRQOL and physical functioning compared to patients without chronic gout. The results were published in the print edition of the July 2012 issue of The Journal of Rheumatology.

"The significant improvements we observed in KRYSTEXXA-treated patients' pain, physical function and health-related quality of life are important as the daily burden of untreated RCG can be tremendous for these patients," said Vibeke Strand, M.D., Adjunct Clinical Professor, Division of Immunology and Rheumatology, Stanford University School of Medicine. "These improvements in quality of life measures also translate into meaningful savings in terms of cumulative treatment costs for patients with RCG."

The pre-specified, pooled analysis evaluated patient-reported outcomes from two replicate, randomized, double-blind, placebo-controlled Phase III studies of patients receiving treatment with KRYSTEXXA 8 mg every two weeks or every four weeks compared to placebo. At weeks one (baseline), 13, 19 and 25, investigators measured patient-reported HRQOL outcomes through four widely utilized assessment tools, namely, Medical Outcomes Study Short Form-36 (SF-36) physical component summary scores, the Health Assessment Questionnaire-Disability Index (HAQ-DI), patient global assessment of disease activity (PtGA) and pain by visual analog scale (VAS).

Results at week 25 demonstrated that mean improvements from baseline were statistically significant and exceeded minimum clinically important differences (MCID) in patients treated with KRYSTEXXA 8 mg every two weeks, the approved dose and schedule. The data demonstrate that at least 50% of patients showed improvements in HRQOL parameters except for HAQ-DI in which 45% of patients showed improvements compared to placebo. Monthly pegloticase also improved HRQOL but the effects were not as robust as the bi-weekly treatment group. There was little to no improvement seen in the placebo group.

"This study underscores the severity of functional impairment experienced by many RCG patients and there is no other treatment to date that has shown to be effective in improving HRQOL and physical function in these patients as that demonstrated by KRYSTEXXA," said Kenneth Bahrt, M.D., Senior Vice President and Chief Medical Officer of Savient. "We are pleased to have this analysis accepted for publication by The Journal of Rheumatology, which is a prestigious peer reviewed journal."


'/>"/>

Contact: Mary Coleman
information@savient.com
732-418‑9300
Savient Pharmaceuticals
Source:Eurekalert

Related medicine news :

1. Genome-wide analysis shows previously undetected abnormalities in parents of affected children
2. Analysis will examine safety of in-hospital underwater births
3. Biochip-based device for cell analysis
4. Zinc Pills May Shorten Colds, Analysis Suggests
5. Analysis Finds Clinical Trials Often Small, of Poor Quality
6. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
7. Lung Cancer Screening Might Pay Off, Analysis Shows
8. Reach2HD, a Phase II study in Huntingtons disease, launched
9. ALS patients differ on treatment choices in later phases of disease
10. Hybrid vaccine demonstrates potential to prevent breast cancer recurrence
11. Automated insulin dosage titration system demonstrates positive clinical study results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... Malvern, PA (PRWEB) , ... June 20, 2017 , ... ... that specialize in minimally invasive techniques to treat and manage a wide range of ... a strategic rebranding initiative. With more than 65 centers represented by more than 40 ...
(Date:6/20/2017)... ... June 20, 2017 , ... EdChoice and the American ... choice can promote economic development in economically distressed urban areas. The first report ... report, contributed to the economic development of the city of Santa Ana, California. ...
(Date:6/20/2017)... , ... June 20, 2017 , ... AMC Health ... expansion and success in the clinical trials market. Similar to its approach in demonstrating ... in the clinical trials marketplace by proving the value of eVisits to support virtual ...
(Date:6/20/2017)... ... June 20, 2017 , ... Leading dental clinicians, Drs. Ashlyn Price, Autumn Mayers ... PaX-i and Anatomage systems. With advanced digital images and modeling capabilities, the dentists identify ... precisely and restore oral health for those who are missing teeth in ...
(Date:6/20/2017)... ... ... As a leading dental practice, Wall Centre Dental supports Stroke Awareness Month by ... gums in Vancouver, BC, may be developing gingivitis, the first stage of gum ... diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer laser gum therapy to ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... plc (NASDAQ: ENDP ) announced today that ... in a fireside chat at Goldman Sachs, 38 th ... 10:40 a.m. PT / 1:40 p.m. ET. The conference will ... Verdes, CA. A live webcast and ... Company,s website at http://www.endo.com/investors/overview . Participants should allow approximately ...
(Date:5/24/2017)... Va. , May 24, 2017  ivWatch ... Original Equipment Manufacturer (OEM) Board to enable seamless ... with patient monitoring systems, infusion pumps and other ... OEMs will be able to help health care ... and reduced risks related to IV therapy. ...
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
Breaking Medicine Technology: